Tokyo, July 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062142) titled 'Evaluation of the current impact and utility of cancer genomic testing in Japan' on July 6.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center Research Institute
Condition:
Condition - Solid cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - 1. To evaluate overall survival (OS) in patients who received molecularly targeted therapy (MBRT) recommended by the Expert Panel (EP) after comprehensive genomic profiling (CGP) testing, compared to patients who received standard of care (SOC) treatment.
2. To assess the post-CGP Cox proportional hazard ratio after stratifying patients by the timing of CGP testing (early vs. late in disease course).
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Those registered in C-CAT between June 2019 and September 2025, and who, at the time of receiving cancer gene panel testing provided informed consent. The study will target the top 10 cancer types in the C-CAT database, as well as cancer types for which clinical trials are ongoing with entry criteria based on the presence or absence of gene mutations.
Key exclusion criteria - Individuals who meet any of the following criteria will be excluded from the study:
1. Patients whose diagnostic information is missing
2. Patients missing any of the key data required for analysis
Target Size - 50000
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 02 Month 03 Day
Date of IRB - 2026 Year 02 Month 06 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2026 Year 12 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071114
Disclaimer: Curated by HT Syndication.
